Vericel Corporation (NASDAQ:VCEL) will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website vcel.com
Earnings Expectation
Vericel Corporation is reporting third quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, VCEL is expected to report 3Q20 loss of $ 0.02 per share from revenue of $ 31.06 million. For the full year, analysts anticipate top line of $ 122.03 million, while looking forward to loss of $ 0.11 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 32.00 million ~ $ 32.00 million
Full Year 2020 topline are forecasted in a range of$ 141.00 million ~ $ 146.00 million
Click Here For More Historical Outlooks Of Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
